Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory...

Area of Science:

• Cardiovascular Research
• Molecular Cardiology
• Pharmacology

Background:

• Normal calcium (Ca2+) regulatory protein expression is vital for myocardial function.
• Left ventricular (LV) remodelling and dysfunction characterize heart failure.
• Statins, like rosuvastatin, are primarily known for lipid-lowering effects.

Purpose of the Study:

• To investigate if rosuvastatin can prevent LV remodelling and dysfunction in a failing heart model.
• To explore the potential association between rosuvastatin's effects and alterations in Ca2+-regulatory proteins.
• To examine the impact of rosuvastatin on specific proteins like SERCA2a and phospholamban.

Main Methods:

• A rat model of myocardial infarction (MI) was used to induce cardiac dysfunction.
• Rats received rosuvastatin (10 mg/kg/day) or a placebo for 10 weeks.
• Evaluated LV remodelling, function, SERCA2a, phospholamban (PLB), phospho-PLB (pSer16-PLB) expression, SERCA activity, and cytokine levels (IL-6, IL-10).

Main Results:

• Rosuvastatin treatment prevented LV remodelling and dysfunction post-MI.
• It normalized sarcoplasmic reticulum Ca2+ ATPase (SERCA)2a expression and increased SERCA activity.
• Rosuvastatin increased pSer16-PLB levels, reduced IL-6, and elevated IL-10, without affecting serum lipids or PLB expression.

Conclusions:

• Rosuvastatin effectively prevents cardiac remodelling and dysfunction in a failing heart model.
• The mechanism involves normalizing SERCA2a expression, SERCA activity, and pSer16-PLB levels.
• Cytokine modulation by rosuvastatin contributes to its cardioprotective effects, independent of lipid-lowering.